Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
Management of glioblastoma: State of the art and future directions
Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for
patients with this disease is poor, with a median survival of< 2 years. There is a slight …
patients with this disease is poor, with a median survival of< 2 years. There is a slight …
Association of maximal extent of resection of contrast-enhanced and non–contrast-enhanced tumor with survival within molecular subgroups of patients with newly …
Importance Per the World Health Organization 2016 integrative classification, newly
diagnosed glioblastomas are separated into isocitrate dehydrogenase gene 1 or 2 (IDH) …
diagnosed glioblastomas are separated into isocitrate dehydrogenase gene 1 or 2 (IDH) …
Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection
J Zhang, C Chen, A Li, W Jing, P Sun, X Huang… - Nature …, 2021 - nature.com
Immunotherapies have revolutionized intervention strategies for many primary cancers, but
have not improved the outcomes of glioblastoma multiforme (GBM), which remains one of …
have not improved the outcomes of glioblastoma multiforme (GBM), which remains one of …
Current FDA-approved therapies for high-grade malignant gliomas
JP Fisher, DC Adamson - Biomedicines, 2021 - mdpi.com
The standard of care (SOC) for high-grade gliomas (HGG) is maximally safe surgical
resection, followed by concurrent radiation therapy (RT) and temozolomide (TMZ) for 6 …
resection, followed by concurrent radiation therapy (RT) and temozolomide (TMZ) for 6 …
Frontiers in the treatment of glioblastoma: Past, present and emerging
Glioblastoma (GBM) is one of the most aggressive cancers of the brain. Despite extensive
research over the last several decades, the survival rates for GBM have not improved and …
research over the last several decades, the survival rates for GBM have not improved and …
[HTML][HTML] Evidence-based recommendations on categories for extent of resection in diffuse glioma
P Karschnia, MA Vogelbaum, M van den Bent… - European Journal of …, 2021 - Elsevier
Surgical resection represents the standard of care in diffuse glioma, and more extensive
tumour resection appears to be associated with favourable outcome. Up to now, terminology …
tumour resection appears to be associated with favourable outcome. Up to now, terminology …
[HTML][HTML] Glioblastoma: overview of disease and treatment
ME Davis - Clinical journal of oncology nursing, 2016 - ncbi.nlm.nih.gov
Background Glioblastoma (GBM) is the most common and aggressive malignant brain tumor
in adults. Current treatment options at diagnosis are multimodal and include surgical …
in adults. Current treatment options at diagnosis are multimodal and include surgical …
Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence
J Xue, Z Zhao, L Zhang, L Xue, S Shen, Y Wen… - Nature …, 2017 - nature.com
Cell-mediated drug-delivery systems have received considerable attention for their
enhanced therapeutic specificity and efficacy in cancer treatment. Neutrophils (NEs), the …
enhanced therapeutic specificity and efficacy in cancer treatment. Neutrophils (NEs), the …
Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data
The blood–brain barrier (BBB) excludes the vast majority of cancer therapeutics from normal
brain. However, the importance of the BBB in limiting drug delivery and efficacy is …
brain. However, the importance of the BBB in limiting drug delivery and efficacy is …